Page 87 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 87
Parallel Session: Viral Hepatitis C: Clinical Hall D
Chairs:
Thomas Berg, Germany
Stanislas Pol, France
ABSTRACT LEDIPASVIR/SOFOSBUVIR TREATMENT RESULTS SCIENTIFIC PROGRAMME
O056 IN HIGH SVR RATES IN PATIENTS WITH CHRONIC
16:00 - 16:15 GENOTYPE 4 AND 5 HCV INFECTION
Armand Abergel, France
ABSTRACT
O057 LONG-TERM FOLLOW-UP OF TREATMENT-EMERGENT
16:15 - 16:30 RESISTANCE-ASSOCIATED VARIANTS IN NS3, NS5A
AND NS5B WITH PARITAPREVIR/R-, OMBITASVIR- AND
ABSTRACT DASABUVIR-BASED REGIMENS
O058 Preethi Krishnan, The United States
16:30 - 16:45
INCREASED CANCER RATES IN PATIENTS WITH
ABSTRACT CHRONIC HEPATITIS C: AN ANALYSIS OF THE CANCER
O059 REGISTRY IN A LARGE U.S. HEALTH MAINTENANCE
16:45 - 17:00 ORGANIZATION
Anders H. Nyberg, The United States
ABSTRACT
O060 LONG-TERM PERSISTENCE OF HCV NS5A VARIANTS
17:00 - 17:15 AFTER TREATMENT WITH NS5A INHIBITOR LEDIPASVIR
David Wyles, The United States
ABSTRACT
O061 MIR-17/92 EXPRESSION PATTERN: A MOLECULAR
17:15 - 17:30 SIGNATURE OF HCV-RELATED MIXED
CRYOGLOBULINEMIA
ABSTRACT Alessia Piluso, Italy
O062
17:30 - 17:45 INCIDENCE OF HEPATITIS C REINFECTION FOLLOWING
SUSTAINED VIROLOGICAL RESPONSE – A SEVEN YEAR
ABSTRACT FOLLOW-UP OF SCANDINAVIAN PATIENTS INFECTED
O063 THROUGH INJECTING DRUG USE
17:45 - 18:00 Håvard Midgard, Norway
FACTORS ASSOCIATED WITH SPONTANEOUS
CLEARANCE OF CHRONIC HEPATITIS C VIRUS
INFECTION: A RETROSPECTIVE CASE CONTROL STUDY
Naomi Bulteel, The United Kingdom
HCV REINFECTION CASES IN PHASE 3 STUDIES OF
SOFOSBUVIR
Christoph Sarrazin, Germany
Vienna, Austria • April 22–26, 2015 87
Chairs:
Thomas Berg, Germany
Stanislas Pol, France
ABSTRACT LEDIPASVIR/SOFOSBUVIR TREATMENT RESULTS SCIENTIFIC PROGRAMME
O056 IN HIGH SVR RATES IN PATIENTS WITH CHRONIC
16:00 - 16:15 GENOTYPE 4 AND 5 HCV INFECTION
Armand Abergel, France
ABSTRACT
O057 LONG-TERM FOLLOW-UP OF TREATMENT-EMERGENT
16:15 - 16:30 RESISTANCE-ASSOCIATED VARIANTS IN NS3, NS5A
AND NS5B WITH PARITAPREVIR/R-, OMBITASVIR- AND
ABSTRACT DASABUVIR-BASED REGIMENS
O058 Preethi Krishnan, The United States
16:30 - 16:45
INCREASED CANCER RATES IN PATIENTS WITH
ABSTRACT CHRONIC HEPATITIS C: AN ANALYSIS OF THE CANCER
O059 REGISTRY IN A LARGE U.S. HEALTH MAINTENANCE
16:45 - 17:00 ORGANIZATION
Anders H. Nyberg, The United States
ABSTRACT
O060 LONG-TERM PERSISTENCE OF HCV NS5A VARIANTS
17:00 - 17:15 AFTER TREATMENT WITH NS5A INHIBITOR LEDIPASVIR
David Wyles, The United States
ABSTRACT
O061 MIR-17/92 EXPRESSION PATTERN: A MOLECULAR
17:15 - 17:30 SIGNATURE OF HCV-RELATED MIXED
CRYOGLOBULINEMIA
ABSTRACT Alessia Piluso, Italy
O062
17:30 - 17:45 INCIDENCE OF HEPATITIS C REINFECTION FOLLOWING
SUSTAINED VIROLOGICAL RESPONSE – A SEVEN YEAR
ABSTRACT FOLLOW-UP OF SCANDINAVIAN PATIENTS INFECTED
O063 THROUGH INJECTING DRUG USE
17:45 - 18:00 Håvard Midgard, Norway
FACTORS ASSOCIATED WITH SPONTANEOUS
CLEARANCE OF CHRONIC HEPATITIS C VIRUS
INFECTION: A RETROSPECTIVE CASE CONTROL STUDY
Naomi Bulteel, The United Kingdom
HCV REINFECTION CASES IN PHASE 3 STUDIES OF
SOFOSBUVIR
Christoph Sarrazin, Germany
Vienna, Austria • April 22–26, 2015 87
